Flavopiridol, an inhibitor of cyclin-dependent kinases and other protein kinases, induces in vitro apoptosis of malignant cells from B-cell chronic lymphocytic leukemia (B-CLL). Previously, we reported that nitric oxide (NO), produced by an inducible NO synthase (iNOS), spontaneously expressed by the B-CLL cells, contributed to their deficiency in apoptosis. In the present work, we show that ex vivo treatment of leukemic cells from B-CLL patients with flavopiridol results in the inhibition of iNOS expression, as determined by immunofluorescence and Western blotting, and in a marked inhibition of NO production measured in situ with a specific fluorescent probe (DAF-2 DA). These effects are accompanied by membrane, mitochondrial and nuclear events of apoptosis. Flavopiridol exposure also results in the stimulation of caspase 3 activity and in caspasedependent cleavage of p27 kip1 , a negative regulator of the cell cycle, which is overexpressed in B-CLL. Thus, flavopiridol is capable of downregulating both iNOS and p27 kip1 expression in B-CLL cells. Furthermore, flavopiridol-promoted apoptosis is partly reverted by an NO donor, suggesting that inhibition of the NO pathway could participate in the apoptotic effects of flavopiridol on the leukemic cells.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL), the most frequent form of leukemia in Western countries, is resistant to chemotherapy and presently remains an uncurable disease. It is characterized by the accumulation of quiescent CD5 þ CD23 þ B lymphocytes as a result of defective apoptosis, rather than lack control of cell proliferation, inasmuch as 95% of the leukemic cells are cell cycle-arrested. 1 The mechanisms leading to this deficient apoptosis are not clearly understood. High expression levels of the antiapoptotic molecule Bcl-2 and other members of the Bcl-2 family are frequently observed in the leukemic cells. [2] [3] [4] However, B-CLL is not characterized by the t(14;18) translocation, which is associated with Bcl-2 overexpression in follicular B-cell lymphoma. Previously, we reported that B-CLL cells express high levels of p27 kip1 , a negative regulator of the cell cycle, 5 and that these levels are inversely related to the susceptibility of the leukemic cells to apoptosis in vitro. 6 Furthermore, we also showed the constitutive expression of a functional NO synthase (NOS) of the inducible type (iNOS) in B-CLL cells, which was absent in normal B lymphocytes, 7 a result confirmed by a study also showing that IFN-g and IL-4 stimulated iNOS expression in the leukemic cells. 8 In our study, the inhibition of endogenous NO release by ex vivo treatment of the leukemic cells with NOS inhibitors was found to result in the induction of apoptosis, indicating that the NO pathway may contribute to prevent programmed cell death in B-CLL. 7 Thus, drugs aimed at downregulating iNOS expression or activity could be of potential therapeutic interest for this leukemia.
Flavopiridol is a semisynthetic flavone originally described as an inhibitor of cyclin-dependent kinases and other protein kinases, due to its interaction with ATP-binding sites (see Sedlacek 9 for review). This compound showed in vivo antitumor effects, and is currently under clinical evaluation for the therapy of various malignant diseases, including B-CLL (see Senderowicz 10 and Zhai et al 11 for reviews). The antiproliferative properties of flavopiridol were extensively studied and the molecular mechanism of action is now well defined: the flavone blocks cell cycle progression at G1 and G2 interfaces by inhibiting Cdk2, 4 and 7 (see Sedlacek 9 and Senderowicz 10 for reviews). Besides, flavopiridol is also active on noncycling cells through proapoptotic properties that were described in B-CLL cell lines and patients' cells in vitro.
12,13 A p53-independent, but caspase 3-dependent, mechanism was evidenced. 13 Flavopiridol was also found to decrease the levels of the antiapoptotic proteins Mcl-1 and XIAP. 4 With respect to the effects of the flavone on Bcl-2 expression, divergent results were reported. 3, 4, [12] [13] [14] Thus, the mechanisms whereby flavopiridol induces apoptosis are not fully elucidated.
In the present work, we investigated whether flavopiridol, in addition to its proapoptotic effects, could act on the NO pathway in leukemic cells from B-CLL patients in vitro. As NO is known to inhibit caspase activity in B-CLL 15 and p27 kip1 to be downregulated through a caspase-dependent cleavage, 16 we also studied the effect of flavopiridol on p27 kip1 expression. Our results demonstrate that flavopiridol treatment results in the inhibition of both iNOS expression and NO production, and in p27 kip1 downregulation.
Materials and methods

Patients and cells
A total of 29 untreated patients with Binet stage A B-CLL were selected. Diagnosis was established according to the international CLL workshop criteria, including lymphocyte morphology and coexpression of CD5, CD20 and CD23 antigens. 17 These patients included 17 men and 12 women with a mean age of 62.2 years (range 46-78 years), and the time since diagnosis varied between 0 (newly diagnosed patients) and 10 years. The patients were randomly chosen for each type of experiment inasmuch as CD38 expression, cytogenetics and V H status were only available for a fraction of them, thus hampering a riskgroup analysis. Leukemic cells were freshly purified from the peripheral blood as previously described, providing more than 94% cells of the B-CLL phenotype. 7 All cell cultures were performed with 2 Â 10 6 cells/ml in RPMI-1640 medium supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 16 mg/ml gentamycin, 10 mM HEPES and 10% heat-inactivated fetal calf serum (Myoclone super plus, Gibco BRL, Cergy-Pontoise, France) at 371C in a humidified atmosphere containing 5% CO 2 .
Reagents
Flavopiridol was kindly provided by Aventis Pharmaceuticals (Bridgewater, NJ, USA). A 10 mM stock solution was prepared in DMSO, aliquoted and kept at À201C. Z-VAD-fmk was purchased from Biomol (Plymouth Meeting, PA, USA). Except when otherwise stated, FITC-conjugated mAbs were obtained from Becton Dickinson (Mountain View, CA, USA). The slowreleasing NO donor NOC-18 or DETA-NO (half-life ¼ 5 h at physiological pH) of the NONOate family, which mimics in part the effect of NO released by an iNOS, was purchased from Alexis Biochemicals (Q-BIOgene, Illkirch, France), as the selective iNOS inhibitor L-NIL.dihydrochloride (L-N6-(1-iminoethyl)-lysine Á 2HCl). The other reagents and chemicals were obtained from Sigma (St Louis, MO, USA).
Annexin V-binding assay
Externalization of phosphatidylserine (PS) is an event occurring during the induction of apoptosis before membrane disruption. Apoptosis was therefore quantified by the percentage of cells expressing PS at the outer leaflet of the plasma membrane. This was measured by the specific fixation of FITC-conjugated annexin V (Bender Medsystems, Vienna, Austria) with or without simultaneous labeling with propidium iodide (PI), according to a modification of the original technique. 18 The cellular uptake of PI indicates cell membrane disruption generally observed during cell necrosis or late apoptosis. The percentages of annexin V-FITC and PI-positive and -negative cells were determined by flow cytometry on a FACScan (Becton Dickinson).
DNA fragmentation assay
Apoptosis-induced DNA fragmentation was evaluated by quantification of cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) using an ELISA with antihistone and anti-DNA fragment mAbs provided in a kit (Cell Death Detection ELISA PLUS , Roche Diagnostics, Indianapolis, IN, USA). Cells were lysed and processed according to the manufacturer's specifications, and the formation of nucleosomes in the cytoplasm was estimated using a classical streptavidinbiotin-peroxidase system, revealed by a colorimetric reaction and reading of the absorbance at 405 nm with a microplate reader spectrophotometer (Wallac Victor-2, Perkin-Elmer, Norwalk, MT, USA). Statistical analysis was performed with the twotailed Student's t-test.
Caspase 3-activity assay
Caspase 3 activity was measured in cell lysates by the capacity to cleave its specific tetrapeptide substrate DEVD. Briefly, cultured cells were incubated at 2 Â 10 6 /ml in lysis buffer (50 mM HEPES, 0.1% CHAPS, 1 mM DTT, 0.1 mM EDTA, pH ¼ 7.4) for 5 min at 41C. The cytosolic extracts were collected by centrifugation and their protein concentration was determined using the Bio-Rad assay (Bio-Rad laboratories, Mü nchen, Germany). Aliquots of 20 mg were then incubated in the presence of either the fluorogenic DEVD-aminocoumarin (DEVD-AMC) or the colorimetric DEVD-paranitroaniline (DEVD-pNA) caspase 3 substrate (both from Biomol). The release of AMC resulting from the cleavage of the fluorogenic substrate was recorded with a Victor-2 microplate reader (excitation wavelength 380 nm; emission wavelength 460 nm) every 10 min during 2 h. The conditions were the same for the colorimetric substrate, except that absorbance was recorded at 405 nm. Recombinant human caspase 3 was assayed in parallel as a positive control, and the substrate alone was used as a negative control. The specificity of the reaction was assessed by the addition of the unlabeled Ac-DEVD-CHO caspase 3 inhibitor (Biomol).
Analysis of the mitochondrial transmembrane potential DCm
The Mit-E-C mitochondrial permeability detection kit (Biomol) was used according to the manufacturer's specifications. Briefly, washed cells were incubated at 2 Â 10 6 cells/ml in an Mit-E-C assay buffer containing the fluorescent probe JC-1 for 15 min at 371C. After washings, aliquots of cells were distributed in triplicate in assay buffer in the wells of a 96-well (black with clear flat bottom) Costar microtitration plate (Corning Inc., Corning, NY, USA), and directly analyzed for fluorescence in a microplate reader cytofluorometer (Victor-2), with a simultaneous detection of the green and red fluorescences (excitation wavelength 485 nm, emission wavelength 525 nm, and excitation wavelength 485 nm, emission wavelength 595 nm, respectively). The dissipation of DCm is characterized by a significant shift of the red to the green fluorescence and therefore by a reduction of the red/green fluorescence ratio.
Detection of Bcl-2
The expression of Bcl-2 protein was quantified by ELISA (human Bcl-2 ELISA kit from Bender Medsystems). Briefly, viable cells were lysed and diluted lysates were incubated in anti-Bcl-2 mAb-coated 96-well microtitration plates in the presence of FITC-conjugated anti-Bcl-2 mAb. After incubation with a horseradish peroxidase (HRP)-conjugated anti-FITC mAb, the FITC immobilized by the sandwich was quantified through a classical HRP reaction with a specific substrate, and reading of the absorbance at 450 nm using a Victor-2 microplate reader. The Bcl-2 content in triplicate samples was estimated (s.d.o10%) with the aid of a standard curve prepared with six recombinant human Bcl-2 standard concentrations.
Immunofluorescence studies
The expression of iNOS protein was determined by immunofluorescence using a fluoresceinated anti-iNOS mAb (FITCmacNOS, clone 6; BD Transduction Laboratories, Heidelberg, Germany) directed against a peptide fragment corresponding to the amino acids 961-1144 of murine iNOS, and recognizes the human enzyme. Briefly, cells were permeabilized with the Cytoperm kit (Serotec, Oxford, UK), and incubated for 30 min at 41C with either the FITC-conjugated anti-iNOS mAb or an isotype-matched control mAb (IgG 2a -FITC, Becton Dickinson). Cells were then washed and analyzed by flow cytometry on a FACScan: the viable cells were gated according to their FSC/SSC profile and the percentage of fluorescent cells was determined from 45000 viable cells, after subtraction of the isotype control fluorescence, with the aid of the Cell Quest and Procyt softwares. The statistical differences between the isotype and anti-iNOS antibody-labeled cells were analyzed using the Kolmogorov-Smirnov's test.
Western blot analysis
To investigate the expression of iNOS and p27 kip1 by Western blotting, cells were lysed with RIPA buffer (10 mM Tris-pH ¼ 7.5, 1% Na deoxycholate, 1% Nonidet-P40, 150 mM NaCl, 0.1% SDS, 1 mM PMSF, 1 mM Na orthovanadate, 10 mM b-glycerophosphate, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 10 mg/ ml pepstatin) for 30 min at 41C. The protein content was measured and equal amounts of the cell lysates (generally 50 mg of proteins in SDS-reducing buffer) were electrophoresed by SDS-PAGE (either 12% for p27 or 8% for iNOS, or a gradient gel for simultaneous analysis). Separated proteins were then electrotransferred overnight at 41C on Immobilon-P membranes (Millipore, Bedford, MA, USA). The membranes were then saturated for 1 h with 5% nonfat milk in TN buffer (10 mM TrispH ¼ 8, 200 mM NaCl) containing 0.1% Tween 20, and further incubated for 2 h with the antibody recognizing the molecule of interest at 0.5 mg/ml in TN buffer containing 3% nonfat milk and 0.05% Tween 20. Two polyclonal rabbit antibodies (Santa Cruz Biotechnology, CA, USA) were used: NOS-2 (N-20) P, an antiiNOS antibody, and p27 (N-20), an anti-p27 kip1 antibody, recognizing both the p27 and its cleavage product p23. After membrane washings, the immunoblotted proteins were revealed with an HRP-goat anti-rabbit antibody for 1 h. The membranes were washed again and developed with a system of chemiluminescence (ECL; Amersham Pharmacia, Uppsala, Sweden). Finally, the membranes were also hybridized with a mouse antib-actin mAb (clone C4; ICN, Costa Mesa, CA, USA) for protein content monitoring and standardization.
Endogenous NO production
The production of NO was evaluated in situ using the NOspecific probe diaminofluorescein 2-diacetate (DAF-2 DA; Calbiochem, La Jolla, CA, USA) and cytofluorometry analysis. Briefly, cells were washed, adjusted to 10 6 /ml in culture medium and incubated with 10 mM of the fluorescent probe for 1 h at 371C in the dark. The DAF-2 DA-labeled cells were then washed and resuspended in 1 ml of prewarmed (371C) RPMI-1640 medium without phenol red, supplemented with 1 mM arginine in the wells of a 24-well tray (Costar). Fluorescence (excitation 485 nm, emission 535 nm) was then recorded every 10 min during 2 h in a cytofluorometer thermostated at 371C. The results are expressed as fluorescence intensity as a function of time. The specificity of the probe was monitored by the addition of NOS inhibitors during the assay, which resulted in fluorescence suppression.
Results
Flavopiridol inhibits iNOS expression in leukemic cells from B-CLL patients
The in vitro effects of flavopiridol on iNOS protein expression were investigated in leukemic cells from B-CLL patients. As measured by immunofluorescence with an anti-iNOS mAb on permeabilized cells and flow cytometry analysis, a significant but variable percentage of iNOS-positive cells was consistently found (as exemplified in Table 1 ), in agreement with our previous data. 7 Treatment with different flavopiridol concentrations (50, 100, 500 nM, 1 and 5 mM) resulted in a dose-dependent decrease in the percentage of iNOS-positive cells in all the patients tested, and the maximal effects were observed generally with concentrations o1 mM (ranging from 100 nM to 5 mM) depending on each patient, as illustrated by the four examples presented in Table 1 . As stated previously, patients were randomly selected, but no correlation was observed between the intensity of the response and a risk factor (CD38 expression, V H mutational status), when available. The decrease of iNOS positivity could already be evidenced as early within 3 h of treatment and peaked by 9 h, the maximal effect being maintained until 48-72 h (data not shown). Consequently, a treatment with 1 mM flavopiridol for 18-24 h was chosen for standardization of the conditions in the following experiments.
Western blot experiments performed with B-CLL cell lysates showed that the intensity of the 135 kDa band corresponding to iNOS markedly decreased upon flavopiridol exposure (1 mM for 18 h) vs untreated controls (Figure 1 ). This was attested by the strong reduction in the ratio of the iNOS/b-actin band intensity (mean inhibition 91%; range 83-98%). These results Flavopiridol inhibits iNOS and p27 in B-CLL C Billard et al demonstrate that flavopiridol downregulates the expression of the iNOS protein in B-CLL patients' cells.
Flavopiridol inhibits NO production
We further studied the effects of flavopiridol on endogenous NO production by the leukemic cells using the NO-sensitive fluorescent probe DAF-2 DA. A linear increase of fluorescence over 2 h was detected after DAF-2 DA labeling of untreated control cells. In comparison, ex vivo preincubation of B-CLL cells for 18 h with flavopiridol markedly decreased both the basal amount of intracellular NO (initial fluorescence intensity) and the rate of NO release (fluorescence increase during the 2 h of measurement) in all but one of eight patients tested (Figure 2 ). The observed reductions in the rate of NO release after treatment with 1 mM flavopiridol ranged from 36 to 100%, as estimated by slope decrease, but a significant inhibition was already observed at 0.1 mM (Figure 2h ). Kinetics data revealed that flavopiridol-triggered inhibition of NO production, not detectable after 4 h of incubation, was already maximum at 18 h and remained so until 48 h ( Figure 3 ). These data indicate that flavopiridol-induced inhibition of iNOS expression, as detected by flow cytometry and Western blotting, effectively results in an almost total suppression of NO production by the leukemic cells.
Characteristic features of flavopiridol-induced apoptosis in B-CLL cells
We then examined the relation between the inhibitory effect of flavopiridol on iNOS expression and the ability of the flavone to induce apoptosis of B-CLL cells, which was described by previous studies. First, PS externalization, a cell surface event, was measured by determining the percentage of annexin V-FITC-labeled cells. No necrosis was observed, at least within 24-48 h of treatment with 1 mM flavopiridol, inasmuch as the percentage of PI-positive cells remained very low (2-3%) at that time, both in control and flavopiridol-treated cells. A dosedependent stimulation in annexin V binding following flavopiridol treatment was observed with the same range of flavopiridol concentrations as for iNOS downregulation, and varied between patients, although no correlation could be evidenced with the clinical parameters ( Table 2 ). An inverse relationship between annexin V binding levels and iNOS expression levels was consistently found, as illustrated in Figure 4a . It is noteworthy that PS externalization was already significantly increased after 24 h treatment, but reached a peak at 48 h (not shown), and thus after the inhibition of iNOS expression and NO production, which peaked at 18 h. DNA fragmentation, a nuclear event of apoptosis, was then evaluated by the surrogate release of cytoplasmic histoneassociated DNA fragments using a quantitative ELISA. A highly significant increase in DNA fragmentation was observed upon exposure to 1 mM flavopiridol vs untreated controls (Figure 4b ). This effect was dose-dependent, being already detected at the concentration of 0.1 mM with a maximum at 1 mM; it was also time-dependent, peaking by 24 h, and, therefore, was almost totally extinguished after NO production (not shown).
The antiapoptotic protein Bcl-2 regulates the mitochondrial membrane permeability. Since previous Western blot analysis of the effects of flavopiridol on Bcl-2 expression provided conflicting results, we decided to measure the intracellular content of Bcl-2 with a quantitative ELISA, as described. 19, 20 Bcl-2 levels in B-CLL cells were found to be markedly reduced by flavopiridol (1 mM), as presented in Table 3 . The same concentration of flavopiridol also triggered a dissipation in the leukemic cells of the mitochondrial transmembrane potential DCm, as detected with the specific fluorescent probe JC-1 for the three patients tested (Figure 4c ), confirming that mitochondrial events occur during flavopiridol-stimulated apoptosis of B-CLL cells.
When B-CLL cells were treated with flavopiridol (1 mM, 18 h), the caspase 3 activity in cell lysates markedly increased vs untreated controls, as exemplified for one patient in Figure 4d , and this increase ranged from 1.8-to 2.9-fold for the four patients tested. The data confirm previous studies showing the stimulation of caspase 3 activity by flavopiridol. The latter was Flavopiridol inhibits NO production by B-CLL cells. Cells from eight B-CLL patients were cultured at 2 Â 10 6 /ml for 18 h in the absence (control) or the presence of 1 mM flavopiridol (0.1 mM for patient H). Equal amounts of viable cells (10 6 /ml) were then incubated with the fluorescent probe DAF-2 DA for 1 h at 371C in the dark, washed and fluorescence was recorded every 10 min during 2 h with a cytofluorometer, as detailed in Materials and methods. Autofluorescence was monitored by incubating the cells without DAF-2. The slope of the curve represents the rate of NO production and the initial fluorescence intensity is indicative of the basal intracellular amount of NO. Decreases in the rate of NO production were estimated by slope reduction in flavopiridol-treated cells vs controls, and ranged from 36 to 100% (mean 70% -statistical significance P ¼ 0.0074 was estimated by one-sided unpaired Student's t-test).
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C Billard et al suppressed in the presence of 40 mM of the general caspase inhibitor zVAD-fmk which, in addition, caused a marked reduction in annexin V binding (not shown), indicating that flavopiridol-induced apoptosis is caspase-dependent.
Several reports have demonstrated that the antiapoptotic role of NO was due in part to its capacity to inhibit the catalytic effect of the various caspases through S-nitrosylation and/or oxidation of the cystein that is present in the active site of these enzymes. In agreement with these data, we found that the incubation of B-CLL cells with NOC-18/DETA-NO, a slowreleasing donor at physiological pH, resulted in a dosedependent inhibition of spontaneous caspase 3 activity (Figure 5a) . Conversely, addition of the iNOS inhibitor L-NIL to B-CLL cells elicited a marked increase in caspase 3 activity after 24 h of incubation (Figure 5b) .
Our experiments therefore indicate that flavopiridol elicits multiple events characteristic of the membrane, mitochondrial and nuclear alterations typical of caspase-dependent apoptosis in B-CLL cells, together with a marked downregulation of iNOS expression and NO production. In addition, we show that effector caspase 3 activity is finely regulated by variations in intracellular NO concentration.
Reversal of flavopiridol-induced apoptosis by an NO donor
To investigate whether the suppression of NO production and apoptosis induction by flavopiridol could be causally related, the effects of NOC-18/DETA-NO on flavopiridol-induced stimulation of DNA fragmentation were tested. For this purpose, increasing concentrations of NOC-18 were added to B-CLL cell cultures in the presence of flavopiridol. As shown in Figure 6a , a biphasic effect of the NO donor was evidenced. At high concentrations, NOC-18 alone increased DNA fragmentation, displaying an additive effect with flavopiridol (even synergistic in some experiments); in contrast, low concentrations of NOC-18 (ranging from 0.1 to 1 mM) reverted flavopiridol-induced DNA fragmentation, supporting the hypothesis that the inhibition of the NO pathway was involved in the apoptotic effects of flavopiridol.
We also tested the effects of the iNOS inhibitor L-NIL (1 mM) together with increasing concentrations of flavopiridol. As seen in Figure 6b , L-NIL alone elicited a significant increase in nucleosome enrichment, as expected. Yet, L-NIL did not potentiate the effects of flavopiridol at any concentration, suggesting that both reagents were acting through the same mechanism, that is, inhibition of NO production.
Flavopiridol decreases p27 kip1 expression
The p27 kip1 protein, which is overexpressed by B-CLL cells, 6 is known to be downregulated during apoptosis by caspasedependent cleavage into a p23 form in various cell lines including the B-cell phenotype. 16 We therefore wondered whether the effects of flavopiridol described above could be accompanied by a modulation of p27 kip1 expression in B-CLL cells. To this end, cells from eight patients were induced to apoptosis by flavopiridol under the same experimental conditions as in the above experiments, and Western blotting was performed with an anti-p27 kip1 antibody recognizing both the p27 and its cleaved form, p23 (Figure 7 ). Flavopiridol treatment resulted in a reduction in the intensity of the 27 kDa band, as well as the concomitant appearance of a 23 kDa band. The 27 kDa band was reduced to different extents depending on each patient, but the ratio of 27 kDa/actin band intensity was significantly decreased for all the cases tested (Figure 7b ). The data indicated that p27 kip1 downregulation through cleavage Kinetics of flavopiridol-induced inhibition of NO production. Cells from a representative B-CLL patient were cultured at 2 Â 10 6 /ml for 0, 4 h (a), 18 h (b) and 48 h (c) in the absence (control) or the presence of 1 mM flavopiridol. Equal amounts of viable cells (10 6 /ml) were then incubated with the fluorescent probe DAF-2 DA for 1 h at 371C in the dark and fluorescence was recorded as above.
Flavopiridol inhibits iNOS and p27 in B-CLL C Billard et al into p23 was consistently observed in flavopiridol-treated B-CLL cells. Moreover, this effect of flavopiridol was simultaneously detected to the inhibition of iNOS expression (Figure 7a ). When cells were treated with Z-VAD-fmk (40 mM), a general inhibitor of caspases, the cleavage of p27 was totally reverted, indicating that it was caspase-dependent ( Figure 7c ).
Discussion
At variance with normal B lymphocytes, leukemic B cells from B-CLL patients constitutively express a functional iNOS. 7 We show that flavopiridol inhibits both iNOS expression and NO production in B-CLL cells in vitro, an effect already observed during apoptosis induced by resveratrol 19 and other polyphenols. 20 The latter could be due to a stimulation of iNOS degradation by the proteasome following transcriptional downregulation. Alternatively, post-transcriptional modifications cannot be eliminated; as reported for downregulation of survivin, 21 flavopiridol, through its properties of protein kinase inhibitor, could inactivate iNOS, as the activity as well as the expression of NOS enzymes can be regulated by phosphorylation-dephosphorylation. 22, 23 Experiments are in progress to test the different possibilities.
The effects of flavopiridol on the NO pathway are accompanied by membrane, nuclear and mitochondrial events of apoptosis. Our results confirm that caspase 3 activation and /ml for 48 h in the presence of three different concentrations of flavopiridol or in its absence (controls). The effect of flavopiridol on PS externalization was quantified by measuring the fixation of FITC-annexin V by flow cytometry, as described in Materials and methods. Results are expressed as the percentages of annexin V-positive cells in treated vs untreated cells by subtraction of the control values. The latter did not markedly differ from values measured at time 0, before flavopiridol treatment (maximum increase of about 10% after 2 days incubation). The statistical significance of the data was estimated by the Kolmogorov-Smirnov test. NS (not significant); *Po0.05; **Po0.01; ***Po0.001. NT: not tested. Bcl-2 downregulation are stimulated by the flavone and show a dissipation of the mitochondrial transmembrane potential. Apoptosis and iNOS levels are inversely related and the maximal effect of flavopiridol on iNOS expression is detectable prior to the peaks of PS externalization and DNA fragmentation. Moreover, the suppression of NO production precedes the entry in apoptosis in leukemia B-cell lines (our unpublished results). Thus, inhibition of the NO pathway appears as an early event during flavopiridol-induced apoptosis.
As most B-CLL leukemic B lymphocytes are nonproliferating, 1 the mechanisms whereby flavopiridol induces apoptosis are different from the well-described pathway, which regulates the cell cycle and leads to inhibition of cell division. 9 However, these mechanisms are not fully elucidated. 3, 4, 9, [12] [13] [14] In particular, flavopiridol-induced Bcl-2 downregulation could be the consequence of cell death rather than an initial event of apoptosis. 14 Pepper et al 14 suggested that the flavone acts through a novel cell death pathway that is not related to the Bcl-2 family. Recently, the same group reported that flavopiridolinduced apoptosis in B-CLL cells was associated with the activation of p38 MAP kinase and suppression of ERK activity, thus altering the balance between survival and cell death signals. 24 In connection with this, the constitutive activation of the NO pathway appeared as one of the pathways contributing to the antiapoptotic state in B-CLL. 7 Among different mechanisms implicated in its antiapoptotic properties (reviewed by Kolb 15 ), NO was shown to act by S-nitrosylation and/or oxidation of cysteine residues present in the catalytic site of all caspase members; 25, 26 besides, caspase 3 activity is regulated through S-nitrosylation-denitrosylation. 27 Our results showing that caspase 3 activity in B-CLL is inhibited by an NO donor and reciprocally stimulated by an iNOS inhibitor support this notion. Moreover, flavopiridol-induced apoptosis in B-CLL is caspasedependent. Together, these data suggested that the iNOS expressed by B-CLL cells could be a target for flavopiridol. Our observation that the flavone inhibits iNOS expression and function supports this assumption. The question then arises of the exact role of the decreased NO production as a cause or a consequence of flavopiridol-induced apoptosis. Although the suppression of NO release is achieved before the peaks of several apoptotic events, this could be due to different sensitivities of the techniques. The lack of additivity of the apoptotic effects of flavopiridol and of L-NIL also suggests that both are proceeding through the same mechanism, that is, inhibition of NO production. More important is the finding that low concentrations of an NO donor can partially revert flavopiridol-elicited apoptosis. That high concentrations of the same NO donor can stimulate apoptosis and eventually potentiate the effect of flavopiridol, as already found in the case of fludarabine, 28 is not surprising because the biphasic effects of NO on apoptosis are well known. 15 From our data, it is tempting to speculate that, among other mechanisms such as inhibition of XIAP, 4 flavopiridol-induced downregulation of iNOS expression and suppression of NO release is a molecular switch contributing to subsequent caspase-dependent apoptosis. Experiments are in progress to provide other experimental evidences necessary for supporting this hypothesis.
Our data also show for the first time that flavopiridol treatment of B-CLL cells results in the cleavage of p27 kip1 into the p23 form, a caspase-dependent mechanism, which enables p27 kip1 downregulation during apoptosis, 16 contrary to data reported in a previous work. 13 This discrepancy could result from the use of a different anti-p27 antibody that did not recognize the cleaved p23. However, flavopiridol-induced cleavage of p27 kip1 was found during apoptosis of U937 and other cells. 29, 30 In B-CLL, a decreased expression of p27 kip1 was found after treatment with depsipeptide, another proapoptotic agent of the family of histone deacetylase (HDAC) inhibitors. 31 Interestingly, the cleavage of p27 kip1 described here, which is actually caspase-dependent, occurs simultaneously with iNOS downregulation. Although the causal relationship remains to be demonstrated, p27 kip1 cleavage could be due to the activation of caspases after denitrosylation resulting from flavopiridol-induced inhibition of NO production. That flavopiridol can downregulate p27 kip1 is of interest with respect to the inverse relation between p27 kip1 levels and the susceptibility of B-CLL cells to fludarabine in vitro, as we reported in a previous study. 6 Since p27 kip1 is a negative regulator of the cell cycle, 5 it can be considered as involved in the cell cycle arrest in B-CLL and in the resistance of patients to chemotherapy. Consequently, flavopiridol-induced p27 cleavage could enhance the effects of cycle-dependent chemotherapeutic agents.
While flavopiridol is the subject of great attention and effort, [32] [33] [34] the questions of its in vivo efficacy and of its best regimen have not been answered so far. 11 Initial clinical trials were conducted with a schedule of 72 h continuous infusion to induce cytostatic effects. However, a recent phase I trial of daily flavopiridol as a 1 h bolus allowed repetitive higher peak plasma concentrations. 35 Phase II/III trials using a 1-h infusion schedule are presently being conducted in several tumor types including CLL and show promising results, although the best schedule for combination with standard antitumor agents remains unanswered. 36 Therefore, results of the present study strengthen the interest in designing new clinical trials with flavopiridol in B-CLL. Such trials should utilize schedules of administration achieving optimal apoptosis, inhibition of the NO pathway and p27 kip1 downregulation in the leukemic cells. Timed sequential therapy could be designed where flavopiridol is given prior to cycledependent agents, according to the in vitro model for a clinical trial reported previously. 37 Flavopiridol inhibits iNOS and p27 in B-CLL C Billard et al
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